Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

4.141 +0.671 (+19.34%)
Streaming Delayed Price Updated: 1:22 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
28 29 Next >
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 78 companies made new 52-week lows. 
Via Benzinga
Atai Launches Phase 1 Clinical Trial On Novel Direct-To-Brain Drug Delivery Technology
Clinical stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient ( 
Via Benzinga
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 17, 2022
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 12, 2022
GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48 
Via Benzinga
Novel Psychedelic Compound Show Positive Results For Opioid Use Disorder Treatment
Kratom grows in several Asian countries and has been traditionally used by local communities as a natural home remedy for pain, depression and addiction. 
Via Benzinga
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
From atai Life Sciences
Via GlobeNewswire
Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12 
Via Benzinga
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Psychedelic Stock Gainers And Losers From October 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.51% at $0.63 LOSERS: 
Via Benzinga
Psychedelic Drug Stocks Index Up Slightly This Week
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. 
Via Talk Markets
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22 
Via Benzinga
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for... 
Via Benzinga
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
From atai Life Sciences
Via GlobeNewswire
Allied, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 31.58% at $0.60 
Via Benzinga
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
From atai Life Sciences
Via GlobeNewswire
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 20.50% at $0.58 
Via Benzinga
September Cannabis Category Performances Ranged From -6.3% To -39.0%
The performances of the 5 cannabis categories ranged from -6.3% to -39.0% in September, and are now -13.6% to -67.0%, YTD, depending on the category. The S&P 500, in comparison, was -8.6% in September... 
Via Talk Markets
Major Psychedelic Stocks Continued To Decline In September
There are 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index. Most - but interestingly not all - were down for the week and/or the month. 
Via Talk Markets
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 2.08% at $0.49 
Via Benzinga
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops 
Via Benzinga
Allied, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 6.17% at $3.44 
Via Benzinga
Psychedelic Stock Gainers And Losers From September 28, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 10.48% at $1.16 
Via Benzinga
Biomind Labs, Allied Among Top Psychedelic Movers Of Today
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 11.10% at $1.10 
Via Benzinga
Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage
Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.